PER® International Congress on Oncology & Pathology: Towards Harmonization of Pathology and Oncology Standards

The landscape of immunotherapy biomarkers is rapidly evolving, and future developments are likely to have an impact on patients and clinicians alike.

The field of targeted therapy for patients with non–small cell lung cancer has grown exponentially in recent years, with inhibitors for RET, MET exon 14 skipping, and KRAS G12C mutations transforming the paradigm.

Next-generation sequencing plays a critical role in the diagnosis of patients with myeloid malignancies, but it also plays a necessary role in the identification of passenger mutations and subclonal events that go beyond founding drivers.

Barbara Burtness, MD, discusses the efficacy of immune checkpoint inhibitors in the treatment of patients with head and neck cancer.

Rondell Graham, MBBS, discusses utilizing biomarkers to guide treatment for patients with intrahepatic cholangiocarcinoma.

Endometrial cancer tumor types are traditionally categorized through a combination of histologic molecular subtyping and clinical staging; however, the incorporation of new diagnostic algorithms may have clinical implications for treatment.

Plasma-based next-generation sequencing continues to offer a minimally invasive, highly specific modality to identify patients with actionable alterations in non–small cell lung cancer.

KRAS mutations are found in approximately in 25% of all NSCLC, and it was not until recently that the previously coined “undruggable target” showed signals of actionability with KRAS mutation–specific therapy, tumor-suppressor–specific therapy, and anti-inflammatory therapy.

Matthew Galsky, MD, discusses sequencing questions in urothelial carcinoma.

Jeffrey S. Weber, MD, PhD, discusses research efforts examining neoadjuvant approaches in melanoma.

Balazs Halmos, MD, MS, discusses recent advancements made in non–small cell lung cancer.